BrainStorm announces FDA meeting on Dec 6 to discuss SPA for NurOwn Phase 3b in ALS

BRAINSTORM CELL THERAPEUTICS INC.

FDA granted in-person meeting scheduled for December 6, 2023, to discuss NurOwn's regulatory path in ALS.
BrainStorm plans to seek Special Protocol Assessment (SPA) agreement for a confirmatory Phase 3b trial.
Company aims to align with FDA on re-submission requirements for Biologics License Application (BLA).
CEO states SPA agreement could de-risk program and position company for success.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.